BMPR-IB Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
BML-275 functions as a selective BMPR-IB, exhibiting unique binding affinity that stabilizes the receptor's active conformation. This compound engages in specific molecular interactions that modulate downstream signaling pathways, influencing cellular responses. Its kinetic profile reveals a distinct rate of association and dissociation, allowing for nuanced regulation of receptor activity. Additionally, BML-275's structural properties facilitate effective membrane permeability, enhancing its bioavailability in diverse cellular environments. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin dihydrochloride acts as a selective BMPR-IB, characterized by its ability to disrupt the receptor's inhibitory signaling pathways. This compound demonstrates a unique interaction with the receptor's ligand-binding domain, promoting conformational changes that alter downstream effects. Its reaction kinetics indicate a rapid onset of action, with a specific affinity that allows for targeted modulation of cellular processes. Furthermore, Dorsomorphin's physicochemical properties enhance its solubility, facilitating interactions within various biological systems. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
LY2109761 is a selective inhibitor of TGF-beta receptor type I/II, potentially reducing the phosphorylation and activation of downstream Smad proteins, which may subsequently lead to the inhibition of BMPR-IB expression. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a small molecule that selectively inhibits BMP type I receptor kinases, potentially leading to the reduction of BMPR-IB expression levels and the disruption of its downstream signaling pathways. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1 is a selective BMP inhibitor that targets the BMPR-IB receptor. By binding to BMPR-IB, DMH1 may inhibit its expression and subsequent signaling pathways, affecting cellular processes such as differentiation. | ||||||
K02288 | 1431985-92-0 | sc-488981 | 5 mg | $330.00 | ||
K02288 is a potent and selective inhibitor of BMP type I receptor ALK2, which is structurally related to BMPR-IB. Inhibition of ALK2 may consequently lead to reduced expression of BMPR-IB. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A-83-01 is an inhibitor of TGF-beta type I receptor ALK5, ALK4, and ALK7. By inhibiting these receptors, A-83-01 may indirectly disrupt BMP signaling and reduce BMPR-IB expression. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
Cholecalciferol (RepSox) selectively inhibits ALK5, a TGF-beta type I receptor, potentially leading to reduced BMP signaling and a consequent decrease in BMPR-IB expression. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $327.00 $1377.00 | 2 | |
SB505124 selectively inhibits ALK4 and ALK5, which are part of the TGF-beta receptor complex. By doing so, it may indirectly decrease BMPR-IB expression and affect its signaling pathway. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY364947 is a selective inhibitor of ALK5, which is involved in TGF-beta signaling. By inhibiting ALK5, LY364947 may contribute to reduced BMPR-IB expression and altered cell signaling. | ||||||